FDA Approves Olutasidenib (Rezlidhia) for Certain Patients With AML
The drug has been approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.
Source: medscape.com